open access

Vol 61, No 2 (2010)
Original paper
Submitted: 2013-02-15
Published online: 2010-05-12
Get Citation

Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?

Hanna Pisarek, Marek Pawlikowski, Jolanta Kunert-Radek, Katarzyna Winczyk
Endokrynol Pol 2010;61(2):178-181.

open access

Vol 61, No 2 (2010)
Original Paper
Submitted: 2013-02-15
Published online: 2010-05-12

Abstract


Introduction: The immunohistochemical examination of somatostatin receptor (SSTR) subtypes expression in different endocrine tumours, including pituitary adenomas, revealed membranous or cytoplasmic distribution of SSTR1-5. Currently used long-acting somatostatin analogue octreotide prefers SSTR2 and SSTR5 subtypes. In an earlier study a positive correlation between the summarized score of SSTR2A + SSTR2B expressions and growth hormone (GH) response to octreotide administration was found, independently of receptor distribution within the cell. In this study we searched for the relationship between the GH inhibitory response to acute octreotide administration and SSTR2A, SSTR2B, and SSTR5 cellular localization.
Material and methods: Thirteen acromegalic patients underwent a test of acute administration of octreotide before surgery. The drop in GH was defined as the percentage of the basal value. The pituitary adenomas from these patients were immunostained to determine the hormonal phenotype and expression of SSTR subtypes. The subcellular distribution pattern of SSTR subtypes - membranous or cytoplasmic - was determined.
Results: In the majority of specimens, cytoplasmic localization of receptor subtypes was observed, although membrane or mixed cytoplasmicmembranous localized immunopositivity also occurred. The drop in GH after octreotide administration varied between 57.1-96.7% (mean 82.1%). Among the patients with the cytoplasmic localization of SSTR5, the decrease in GH was significantly higher (92.0 ± 7.0%). A tendency towards the higher response in patients with cytoplasmic localization of SSTR2A and 2B was also observed (86.8% and 87.0%, respectively).
Conclusions: It seems that cytoplasmic localization of SSTR5, SSTR2A, and SSTR2B is connected with enhanced GH inhibition after octreotide administration. It is possible that this somatostatin analogue alters the localization of subtypes SSTR2A and SSTR2B through the receptor internalization. As a consequence, the SSTR-immunopositivity in cell cytoplasm is increased. The cytoplasmic but not the membranous localization is connected with the higher responsiveness to the octreotide in somatotropinomas.
(Pol J Endocrinol 2010; 61 (2): 178-181)

Abstract


Introduction: The immunohistochemical examination of somatostatin receptor (SSTR) subtypes expression in different endocrine tumours, including pituitary adenomas, revealed membranous or cytoplasmic distribution of SSTR1-5. Currently used long-acting somatostatin analogue octreotide prefers SSTR2 and SSTR5 subtypes. In an earlier study a positive correlation between the summarized score of SSTR2A + SSTR2B expressions and growth hormone (GH) response to octreotide administration was found, independently of receptor distribution within the cell. In this study we searched for the relationship between the GH inhibitory response to acute octreotide administration and SSTR2A, SSTR2B, and SSTR5 cellular localization.
Material and methods: Thirteen acromegalic patients underwent a test of acute administration of octreotide before surgery. The drop in GH was defined as the percentage of the basal value. The pituitary adenomas from these patients were immunostained to determine the hormonal phenotype and expression of SSTR subtypes. The subcellular distribution pattern of SSTR subtypes - membranous or cytoplasmic - was determined.
Results: In the majority of specimens, cytoplasmic localization of receptor subtypes was observed, although membrane or mixed cytoplasmicmembranous localized immunopositivity also occurred. The drop in GH after octreotide administration varied between 57.1-96.7% (mean 82.1%). Among the patients with the cytoplasmic localization of SSTR5, the decrease in GH was significantly higher (92.0 ± 7.0%). A tendency towards the higher response in patients with cytoplasmic localization of SSTR2A and 2B was also observed (86.8% and 87.0%, respectively).
Conclusions: It seems that cytoplasmic localization of SSTR5, SSTR2A, and SSTR2B is connected with enhanced GH inhibition after octreotide administration. It is possible that this somatostatin analogue alters the localization of subtypes SSTR2A and SSTR2B through the receptor internalization. As a consequence, the SSTR-immunopositivity in cell cytoplasm is increased. The cytoplasmic but not the membranous localization is connected with the higher responsiveness to the octreotide in somatotropinomas.
(Pol J Endocrinol 2010; 61 (2): 178-181)
Get Citation

Keywords

octreotide; somatostatin receptor subtypes; somatotropinoma

About this article
Title

Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?

Journal

Endokrynologia Polska

Issue

Vol 61, No 2 (2010)

Article type

Original paper

Pages

178-181

Published online

2010-05-12

Page views

580

Article views/downloads

1183

Bibliographic record

Endokrynol Pol 2010;61(2):178-181.

Keywords

octreotide
somatostatin receptor subtypes
somatotropinoma

Authors

Hanna Pisarek
Marek Pawlikowski
Jolanta Kunert-Radek
Katarzyna Winczyk

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl